Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TRDA
#2951
Entrada Therapeutics, Inc. - Common Stock
7.0
7
USD
+3.67%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+3.67%
Monthly Change
-44.37%
6 month change
-30.28%
Year Change
+1.43%
Previous Close
6.8
2
Open
7.0
7
Low
7.0
7
High
7.0
7
Volume
36
Markets
US Stock Market
Healthcare
TRDA
Open full chart
Full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
31.25 M
33.08 M
33.6 M
37.59 M
38.28 M
38.82 M
Valuation ratios
Enterprise value
243.96 M
399.39 M
442.13 M
548.8 M
303.17 M
177.83 M
Price to earnings ratio
-2.1
-4.45
-75.85
10.29
-2.96
-1.64
Price to sales ratio
-1 450.06
—
3.89
3.2
16.73
47.32
Price to cash flow ratio
-2.11
4.48
3.59
16.23
-3.31
-2.07
Price to book ratio
0.36
1.98
2.07
1.57
1.39
0.21
Enterprise value to EBITDA ratio
-4.87
-4.18
-72.48
13.46
-1.93
-1
Profitability ratios
Return on assets %
-0.17
-0.38
-0.01
0.12
-0.38
-0.12
Return on equity %
-0.17
-0.45
-0.03
0.15
-0.47
-0.15
Return on invested capital %
-2 540.47
-1 326.78
0.17
105.53
-840.78
-227.67
Gross margin %
100
—
100
100
100
100
Operating margin %
69.09 K
—
-2.45
22.3
-621.13
-4 834.63
EBITDA margin %
67.68 K
—
-4.73
19.34
-619.46
-4 805.26
Net margin %
69.13 K
—
-5.18
31.13
-565.48
-4 539.09
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
44.46
9.55
2.33
11.15
12.53
13.9
Inventory turnover
—
—
—
—
—
—
Asset turnover
-0
0
0.36
0.42
0.07
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-8.11
-3
4.23
-1.07
-3.11
-3.17
EBIT per share
-8.17
-3.11
-0.1
1.21
-3.82
-4.3
EBITDA per share
-7.99
-3.05
-0.18
1.05
-3.81
-4.27
Total debt per share
—
—
—
—
—
—
Cash per share
46.44
6.03
10.65
10.77
7.15
6.09
Net current asset value per share
47.66
6.71
11.19
11.28
7.4
6.38
Tangible book value per share
47.66
6.79
7.33
10.99
7.4
6.47
Working capital per share
46.58
6
6.38
10.27
6.81
5.92
Book value per share
47.66
6.79
7.33
10.99
7.4
6.47
News
Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics earnings beat by $0.04, revenue fell short of estimates
Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates
Techne (TECH) Beats Q2 Earnings and Revenue Estimates